Idexx Laboratories INC /DE 8-K filings

IDEXX Laboratories announced robust second quarter results, exceeding expectations with significant revenue growth and increased earnings per share, leading to an upward revision of its full-year financial guidance.

IDEXX Laboratories shareholders approved amendments to declassify the Board and grant shareholders the right to call special meetings.

IDEXX Laboratories announced first quarter 2026 results with 14% reported revenue growth and raised full-year guidance, driven by strong performance in its Companion Animal Group.

IDEXX Laboratories announces the mutual agreement for Executive Vice President Nimrata Hunt, PhD, to depart, with a comprehensive separation package totaling $2.29 million.

IDEXX Laboratories announced strong fourth quarter and full year 2025 financial results, driven by pet healthcare innovation and commercial execution, and provided an optimistic 2026 outlook.

IDEXX Laboratories, Inc. announced Michael Erickson, PhD, will become President and CEO on May 12, 2026, succeeding Jonathan Mazelsky, who will transition to Executive Chair before retiring in May 2027.

IDEXX Laboratories, Inc. amended its credit agreement, extending the revolving credit facility to 2030 and the term loan to 2028, while adding a new Swiss subsidiary as a borrower.

IDEXX Laboratories reported strong third-quarter results with double-digit revenue and EPS growth, leading to an upward revision of its full-year 2025 financial guidance.

IDEXX Laboratories, Inc. announced the election of Karen Peacock, a seasoned executive with deep B2B, SaaS software, and AI experience, to its Board of Directors, effective October 6, 2025.

IDEXX Laboratories reported strong second-quarter 2025 financial results, with revenue up 11% and EPS increasing 49%, leading to an upward revision of its full-year 2025 guidance.

IDEXX Laboratories, Inc. announced the election of Joseph L. (Jay) Hooley, former Chair and CEO of State Street Corporation, as an independent Class III Director, expanding its Board to ten members.

IDEXX Laboratories amended its corporate charter and bylaws to eliminate Series A Preferred Stock, remove supermajority voting requirements, and provide officer exculpation, reflecting modern governance practices.

IDEXX Laboratories announced first-quarter results with revenue growth of 4% as reported and 5% organic, and updated its full-year revenue and EPS guidance.

Dr. Asha Collins resigned from IDEXX Laboratories' Board of Directors, effective immediately, leading to a reduction in the board's size.

IDEXX Laboratories announced a 6% revenue growth for both the fourth quarter and full year 2024, alongside a positive outlook for 2025 with projected revenue growth of 4% to 7% and EPS growth of 10% to 15%.

IDEXX Laboratories has adopted a new nonqualified deferred compensation plan allowing eligible employees to defer a portion of their salary, bonus, and stock units.

IDEXX Laboratories has increased its share repurchase program, authorizing the buyback of up to 5 million additional shares of its common stock.

IDEXX Laboratories has announced the retirement of CFO Brian McKeon, effective June 1, 2025, and the appointment of Andrew Emerson as his successor, effective March 1, 2025.

Jonathan Ayers, a former CEO and Chairman of IDEXX Laboratories, has resigned from the company's Board of Directors and its finance committee, effective November 8, 2024.

IDEXX Laboratories has extended its supply agreements with Ortho-Clinical Diagnostics for dry slides used in veterinary chemistry analyzers through the end of 2044, modifying pricing arrangements.

IDEXX Laboratories reported strong third-quarter results but revised its full-year revenue and profit margin outlook due to macroeconomic headwinds impacting veterinary clinic visits.

IDEXX Laboratories announced a 7% revenue increase for the third quarter of 2024, while also adjusting its full-year revenue guidance due to macroeconomic factors impacting veterinary clinic visits.

IDEXX Laboratories announced a 6% reported and 7% organic revenue growth for the second quarter, with a 9% decrease in reported EPS due to a litigation expense, while updating its full-year revenue and EPS guidance.

IDEXX Laboratories has entered into a consulting agreement with former Executive Vice President James F. Polewaczyk and held its 2024 annual shareholder meeting.

IDEXX Laboratories announced a 7% revenue increase for the first quarter of 2024, driven by strong performance in its Companion Animal Group, and updated its full-year revenue and EPS guidance.

IDEXX Laboratories announced a robust fourth quarter and full year 2023 performance, driven by strong growth in its Companion Animal Group (CAG) diagnostics business, and provided an optimistic outlook for 2024.